For the Inventor, By the Inventor

Enter assignee name

Seattle, WA, United States of America

Alpine Immune Sciences, Inc.

USPTO Granted Patents = 29

CIPO Patents = 1

EPO Patents = 7

Forward Citations = 114

Loading Chart...

Loading Chart...

12 inventors (with patents filed for the assignee):

Ryan Swanson (26 out of 30 patents)

Michael G Kornacker (20 out of 26 patents)

Joseph Leon Kuijper (14 out of 44 patents)

4. Mark F Maurer (10 out of 23 patents)

5. Daniel William Demonte (8 out of 8 patents)

6. Lawrence Evans (7 out of 8 patents)

7. Stanford L Peng (3 out of 5 patents)

8. Mark W Rixon (3 out of 43 patents)

9. Stacey R Dillon (3 out of 43 patents)

10. Dan Ardourel (3 out of 3 patents)

11. Steven Dennis Levin (1 out of 1 patent)

12. Michael Kornacker (1 out of 1 patent)

13. Jian Qiu (0 patent)

14. Xicheng Sun (1 patent)

15. Gary J Rosenthal (0 patent)

29 patents: Sort by Forward Citations

1. 12692299 - VARIANT ICOS LIGAND IMMUNOMODULATORY PROTEINS AND RELATED COMPOSITIONS AND METHODS (2026-07-28),

2. 12668634 - CD80 variant immunomodulatory proteins and uses thereof (2026-06-30),

3. 12624087 - CD155 variant immunomodulatory proteins and uses thereof (2026-05-12),

4. 12552853 - CD86 VARIANT IMMUNOMODULATORY PROTEINS AND USES THEREOF (2026-02-17),

5. 12486312 - IMMUNOMODULATORY PROTEINS WITH TUNABLE AFFINITIES (2025-12-02),

6. 12358969 - CTLA-4 variant immunomodulatory proteins and uses thereof (2025-07-15),

7. 12304943 - April and BAFF inhibitory immunomodulatory proteins and methods of use thereof (2025-05-20),

8. 12297253 - Multi-domain immunomodulatory proteins and methods of use thereof (2025-05-13),

9. 12202882 - APRIL and BAFF inhibitory immunomodulatory proteins and methods of use thereof (2025-01-21),

10. 12110339 - ICOS ligand variant immunomodulatory proteins and uses thereof (2024-10-08),

11. 12065476 - PD-1 variant immunomodulatory proteins and uses thereof (2024-08-20),

12. 11834490 - CD112 variant immunomodulatory proteins and uses thereof (2023-12-05),

13. 11753458 - CTLA-4 variant immunomodulatory proteins and uses thereof (2023-09-12),

14. 11732022 - PD-L2 variant immunomodulatory proteins and uses thereof (2023-08-22),

15. 11639375 - CD80 variant immunomodulatory proteins and uses thereof (2023-05-02),

Alpine Immune Sciences, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for patients with cancer and autoimmune/inflammatory diseases. Through their proprietary platform, Directed Evolution, they aim to harness the immune system's power to create next-generation immunotherapies. Alpine's diverse pipeline includes both preclinical and clinical programs targeting various immune checkpoints and immunomodulatory proteins. Their goal is to improve patient outcomes by delivering transformative therapies that restore and enhance immune function.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Sep 22 2026

29 Patents

#78 in Seattle, WA

#261 in Washington

#11,598 in US

#22,493 in the World

Seattle, WA, United States of America

Alpine Immune Sciences, Inc.

Forward Citations = 114

12 inventors:

Ryan Swanson (26 out of 30 patents)

Michael G Kornacker (20 out of 26 patents)

Joseph Leon Kuijper (14 out of 44 patents)

4. Mark F Maurer (10 out of 23 patents)

5. Daniel William Demonte (8 out of 8 patents)

Please report any incorrect information to [email protected]

Loading…